National Cancer Institute, Purchase and Support Contracts Section, 6120 Executive Blvd, EPS/Room 638 MSC 7228, Bethesda MD 20892-7228

B -- ATM GENE SEQUENCING SOL RFQ60053-NS POC Patricia Haun, Contracting Officer, (301) 402-4509. ATM Gene Sequencing in Norwegian AT Families. The National Cancer Institute plans to procure on a sole source basis under authority of FAR 6.302-1, in accordance with 41 U.S.C. 253(c)(1), ATM Gene Sequencing in Norwegian AT Families from Norwegian Radium Hospital, Dept. of Genetics, P.O. Box 56 Montebello, 0310 Oslo, Norway. The purpose of this procurement is to determine specific mutations in the ATM gene in Nowegian families reporting at least one family member with Ataxia Telangiectasia. In order to identify specific mutations in the ATM gene, cell lines need to be established from blood samples and mutations are screened and sequenced using specific techniques. It is proposed that Dr. Annelise Borresen, Chief of Genetics, Institute for Cancer Research, Norwegian Radium Hospital, Oslo, Norway perform the laboratory services required by DCEG for the study of cancer in AT patients and their families in Norway, because Dr. Borresen has sole access to the samples obtained from Norwegian families with AT. As she is the only person experienced in sequencing the ATM gene in these samples. Dr. Borresen is an international expert in the field of molecular genetics and she has developed the CDGE (Constant Denaturing Gel Electrophoresis) to screen mutations, which will be used in this study. This notice of intent is not a request for competitive proposals, however, if an interested party believes they can meet the above specifications, they may submit a statement of capabilities. Information furnished shall include enough material, in sufficient detail, to perform a proper evaluation of their ability to perform. Closing date is 20 days after publication of this notice. SEE Note 22. NO collect calls will be accepted (0116)

Loren Data Corp. http://www.ld.com (SYN# 0017 19960426\B-0002.SOL)